Reaction
Dermatitis Psoriasiform reporting signals
As of the last recalculation, Dermatitis Psoriasiform appears in 2,015 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-AATY (PRR 19.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Aaty | 86 | 19.6 | 19.6 |
| Adalimumab-Fkjp | 83 | 19.3 | 19.3 |
| Adalimumab-Adaz | 92 | 18.8 | 18.9 |
| Infliximab-Dyyb | 40 | 14.4 | 14.4 |
| Secukinumab | 158 | 10.9 | 10.9 |
| Clobetasol Propionate Ointment Usp, 0.05% | 10 | 10.1 | 10.1 |
| Clobetasol Propionate | 10 | 10.0 | 10.0 |
| Infliximab | 189 | 9.8 | 9.8 |
| Leflunomide | 93 | 9.6 | 9.6 |
| Amitriptyline Hydrochloride | 16 | 9.5 | 9.5 |
| Ketoconazole Foam | 13 | 9.1 | 9.1 |
| Ketoconazole Cream, 2% | 13 | 9.1 | 9.1 |
| Ketoconazole | 15 | 9.0 | 9.0 |
| Ixekizumab | 31 | 8.8 | 8.8 |
| Durvalumab | 17 | 8.7 | 8.7 |
| Terbinafine Hydrochloride | 7 | 8.2 | 8.2 |
| Certolizumab Pegol | 80 | 7.3 | 7.3 |
| Pembrolizumab | 71 | 7.2 | 7.2 |
| Ustekinumab | 69 | 7.2 | 7.2 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 16 | 7.1 | 7.1 |
| Adalimumab | 398 | 7.0 | 7.0 |
| Nivolumab | 62 | 6.8 | 6.8 |
| Sulfasalazine | 50 | 6.7 | 6.7 |
| Triamcinolone Acetonide | 17 | 5.7 | 5.7 |
| Golimumab | 46 | 5.6 | 5.6 |
| Atezolizumab | 18 | 4.8 | 4.8 |
| Apalutamide | 5 | 4.4 | 4.4 |
| Abatacept | 48 | 3.6 | 3.6 |
| Nemolizumab-Ilto | 4 | 3.3 | 3.3 |
| Encorafenib | 3 | 3.1 | 3.1 |
| Dupilumab | 114 | 2.5 | 2.5 |
| Bimekizumab | 5 | 2.4 | 2.4 |
| Guselkumab | 8 | 2.3 | 2.3 |
| Apremilast | 23 | 1.6 | 1.6 |
| Salicylic Acid | 3 | 0.6 | 0.6 |